Avalo Therapeutics prices $375M public offering to fund key drug trial
What's the deal? Avalo Therapeutics, a clinical-stage biotech focused on treatments for immune-mediated inflammatory diseases, has priced a $375M underwritten public offering. The Pennsylvania-based company is selling 19.73 million shares of common stock at $17.75 per share, plus pre-funded warrants to purchase an additional 1.4 million shares. The underwriters also have a 30-day option to buy up to 3.17 million more shares. The offering is expected to close on May 7, 2026.
Avalo plans to use the proceeds to advance the clinical development of abdakibart — its lead drug candidate targeting IL-1β — through Phase 3 topline data, along with general corporate purposes.
Leerink Partners, TD Cowen, BofA Securities, Piper Sandler, and Cantor are acting as joint bookrunning managers.
Why now? The timing aligns with Avalo's push toward a critical inflection point: Phase 3 data for abdakibart. Late-stage clinical trials are expensive, and the company clearly needs a substantial cash injection to reach that milestone. The offering was filed under a shelf registration statement declared effective in January 2026, suggesting the company had been preparing for this raise and chose to move when market conditions were favourable.
What could go wrong? The $375M raise comes with significant dilution for existing shareholders — more than 21 million new shares entering the market, with the possibility of another 3.17 million if underwriters exercise their option. For a clinical-stage company with no approved products, the risk is straightforward: if abdakibart's Phase 3 trial disappoints, the stock could face steep losses.
Biotech offerings of this size also tend to pressure share prices in the short term as the market absorbs the new supply.
The signal: A $375M raise for a single-asset clinical-stage biotech reflects renewed investor appetite for high-conviction bets in immunology. The IL-1β pathway has drawn growing interest as a therapeutic target, and Avalo's ability to attract five major bookrunners suggests institutional confidence in abdakibart's potential. The deal fits a broader pattern of biotech companies raising large sums ahead of pivotal data readouts — a sign that capital markets remain open for late-stage clinical stories with clear catalysts.
Read more: ir.avalotx.com
